Radioimmunoassay of haloperidol in human serum. 1977

B R Clark, and B B Tower, and R T Rubin

UI MeSH Term Description Entries
D008722 Methods A series of steps taken in order to conduct research. Techniques,Methodological Studies,Methodological Study,Procedures,Studies, Methodological,Study, Methodological,Method,Procedure,Technique
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

B R Clark, and B B Tower, and R T Rubin
November 1981, Life sciences,
B R Clark, and B B Tower, and R T Rubin
May 1990, Journal of pharmaceutical sciences,
B R Clark, and B B Tower, and R T Rubin
May 1980, Journal of pharmacobio-dynamics,
B R Clark, and B B Tower, and R T Rubin
June 1984, Radioisotopes,
B R Clark, and B B Tower, and R T Rubin
January 1982, Methods in enzymology,
B R Clark, and B B Tower, and R T Rubin
January 1981, International pharmacopsychiatry,
B R Clark, and B B Tower, and R T Rubin
January 1980, European journal of drug metabolism and pharmacokinetics,
B R Clark, and B B Tower, and R T Rubin
January 1985, Journal of immunoassay,
B R Clark, and B B Tower, and R T Rubin
March 1971, Nihon Sanka Fujinka Gakkai zasshi,
B R Clark, and B B Tower, and R T Rubin
June 1981, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!